PLYMOUTH MEETING, PA — Biotechnology company INOVIO (NASDAQ: INO) is making considerable strides with its lead program, INO-3107, aimed at addressing Recurrent Respiratory Papillomatosis (RRP). This progress, backed by encouraging data from a Phase 1/2 trial, presents a beacon of hope for patients afflicted with this often debilitating condition.
RRP, characterized by the growth of benign tumors in the respiratory tract, typically demands regular surgical intervention. INOVIO, however, offers a promising potential alternative. INO-3107, administered in a Phase 1/2 clinical trial for the treatment of HPV-6 and HPV-11-related RRP in adults, has yielded positive results. A significant 81.3% of patient participants reported a decrease in surgical interventions in the year following INO-3107 administration, with 28.1% requiring no surgical intervention at all during or after the dosing period. These findings suggest INO-3107’s efficacy in inducing a strong immune response and potentially reducing the need for surgery.
Amid these promising developments, INOVIO has laid down a roadmap for the future. The company plans to submit a Biological License Application (BLA) to the FDA under the accelerated approval program in the latter half of 2024. The Breakthrough Therapy designation bestowed upon INO-3107 by the FDA, alongside the Orphan Drug designation granted by the European Union, further underscore the drug’s potential to transform treatment options for RRP.
INO-3107, however, is not the only feather in INOVIO’s cap. The company recently announced a clinical collaboration and supply agreement with Coherus BioSciences, intended to advance the development of INO-3112 in combination with LOQTORZI™ (toripalimab-tpzi) for throat cancer. This combination therapy will undergo evaluation in a forthcoming Phase 3 trial, targeting locoregionally advanced, high-risk, HPV-16/18-positive throat cancer patients.
Notably, INOVIO’s strides are not limited to respiratory disease and throat cancer. The company has reported positive results for INO-4201, a potential Ebola booster vaccine, fuels the broader conversation about global medical countermeasures against infectious diseases.
INOVIO’s targeted, strategic initiatives are complemented by judicious financial management. The company ended 2023 with $145.3 million in cash, cash equivalents, and short-term investments, with a projected cash runway leading into the second quarter of 2025. The firm has engaged actively in prioritizing its pipeline, resulting in a 48% reduction in operating expenses from 2022.
With INOVIO poised to submit a BLA for INO-3107, the year 2024 holds great potential. The company stands on the cusp of pioneering advances in DNA medicine, driven by a unifying mission to address pressing medical needs. As Dr. Jacqueline Shea, President and CEO of INOVIO, encapsulates, “We’ve reshaped INOVIO into a company that is focused on commercializing its first product candidate and bringing the benefits of DNA medicine to patients.” As we look ahead, the future of biotechnology seems brighter – and healthier – than ever.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.